Manjeshwar S, Laconi E, Sheikh A, Rao P M, Rajalakshmi S, Sarma D S
Department of Pathology, University of Toronto, Ontario, Canada.
Carcinogenesis. 1994 Sep;15(9):1963-8. doi: 10.1093/carcin/15.9.1963.
One of the proposed mechanisms by which phenobarbital (PB) promotes hepatocarcinogenesis in the rat is by differential mitoinhibition. However, our earlier studies indicated that PB inhibited DNA synthesis in vitro in hepatocytes isolated from both surrounding non-nodular liver and hepatic nodules promoted by orotic acid (OA). Since nodules generated by one promoter need not necessarily be resistant to another promoter, the present study was undertaken to determine whether foci/nodules promoted by PB itself are resistant to the mitoinhibitory effects of PB. Accordingly, rats were initiated with diethylnitrosamine (DENA, 200 mg/kg i.p) and promoted with PB (0.07% of PB as its sodium salt) in their drinking water for 16 or 33 weeks. In vitro studies indicated that PB (3-5 mM) inhibited DNA synthesis induced by epidermal growth factor (EGF) in hepatocytes from surrounding non-nodular liver as well as from nodules promoted by PB for 33 weeks. In another experiment, initiated rats exposed to PB for 33 weeks were subjected to either two-thirds partial hepatectomy (PH) or sham hepatectomy. Hepatocytes were labelled with tritiated thymidine in vivo for 48 h. Autoradiographic analysis indicated that in the presence of PB, the hepatocytes from both foci/nodules and the surrounding non-nodular liver responded to PH to the same extent. In addition, they both responded to PH less efficiently as compared to the corresponding controls. Further, initiated rats exposed to PB for 16 weeks when subjected to PH and killed 4 weeks thereafter, the percentage area occupied by gamma-glutamyltranspeptidase-positive foci/nodules in the PB group increased, but to the same extent as in initiated control rats not exposed to PB. The above results raised an interesting possibility that the lack of resistance of the PB-promoted nodules to the mitoinhibitory effects of PB may be because the PB-promoted nodule does not express a resistant phenotype. To examine this aspect, the response of hepatocytes from 33 week PB-promoted nodules to the mitoinhibitory effects of OA was examined. The results indicated that OA (60-120 microM) inhibited EGF-induced DNA synthesis in hepatocytes isolated from both nodules as well as from surrounding non-nodular liver. These results suggest that PB is a mitoinhibitor but may not provide a strong differential growth advantage to foci/nodules in response to a proliferative stimulus. Further, the nodules promoted by PB do not appear to express the resistant phenotype, defined as being resistant to the mitoinhibitory effects of OA and PB.
苯巴比妥(PB)促进大鼠肝癌发生的一种推测机制是通过差异性有丝分裂抑制。然而,我们早期的研究表明,PB在体外抑制从周围非结节性肝组织以及由乳清酸(OA)诱导产生的肝结节中分离出的肝细胞的DNA合成。由于由一种促癌剂产生的结节不一定对另一种促癌剂具有抗性,因此开展本研究以确定由PB自身诱导产生的病灶/结节是否对PB的有丝分裂抑制作用具有抗性。相应地,用二乙基亚硝胺(DENA,200mg/kg腹腔注射)启动大鼠,并用其饮用水中0.07%的PB钠盐对大鼠进行促癌处理16周或33周。体外研究表明,PB(3-5mM)抑制表皮生长因子(EGF)诱导的周围非结节性肝组织以及由PB促癌33周的结节中的肝细胞的DNA合成。在另一项实验中,将经PB处理33周的启动大鼠进行三分之二部分肝切除术(PH)或假肝切除术。肝细胞在体内用氚标记的胸腺嘧啶核苷标记48小时。放射自显影分析表明,在PB存在的情况下,病灶/结节以及周围非结节性肝组织中的肝细胞对PH的反应程度相同。此外,与相应对照组相比,它们对PH的反应效率均较低。此外,经PB处理16周的启动大鼠在进行PH处理并在4周后处死时,PB组中γ-谷氨酰转肽酶阳性病灶/结节所占的面积百分比增加,但与未接触PB的启动对照大鼠增加的程度相同。上述结果提出了一种有趣的可能性,即PB诱导产生的结节对PB的有丝分裂抑制作用缺乏抗性可能是因为PB诱导产生的结节不表达抗性表型。为了研究这一方面,检测了来自经PB促癌33周的结节中的肝细胞对OA的有丝分裂抑制作用的反应。结果表明,OA(60-120μM)抑制从结节以及周围非结节性肝组织中分离出的肝细胞中EGF诱导的DNA合成。这些结果表明,PB是一种有丝分裂抑制剂,但在对增殖刺激的反应中可能不会为病灶/结节提供强大的差异性生长优势。此外,PB诱导产生的结节似乎不表达抗性表型,即对OA和PB的有丝分裂抑制作用具有抗性。